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Direct measurements of cutaneous drug levels and 
kinetics have long been hampered by lack of appro-
priate methods. Recently, studies have indicated that 
microdialysis, a method of continuous ill vivo sam-
pling of extracellular fluid, may also be performed in 
human skin. The present study was designed to eval-
uate this technique for kinetic analyses of cutaneous 
drug levels. Using a trans dermal nicotine delivery 
system with 35 mg of nicotine as a model, nicotine 
levels were determined in the dialysate of human skin 
by means of high performance liquid chromatogra-
phy. III vitro studies demonstrated that nicotine levels 
in the dialysate strictly correlated with nicotine con-
centrations in the dialyzed medium. In nine healthy 
P harmacologic studies in man generally require sampling of extracellular fluid and subsequent determination of drug levels and drug metabolites. Most sampling from the body is achieved by drawing blood, but blood reflects the chemical composition of the extracellular 
fluid within the general circu lation or from an individual organ 
drained by the vascular system. In dermatology, topical treatment 
regimens aim to achieve relatively high drug levels in the skin as the 
target organ, and aim to keep systemic exposure low. T lus is usually 
11100utored by measuring plasma drug levels after topical application 
of the drug in therapeutic concentrations. However, tlus approach 
does not allow insight into cutaneous drug kinetics and often 
disregards the skin as a metabolizing organ. Thus, in many instances 
it would be lugllly desirable to sample the extracellular fluid of the 
skin directly. Such attempts have mainly used the tecluuque of 
suction blistering, as originally described by Kiistala and Mustakal-
lio in 1967 [1] . The main disadvantages of tlus teclmique are the 
generation of blisters by dermoepidermal separation, wluch pre-
sents a major trauma to the skin, and the creation of a gradient from 
the dermis into the blister cavity, which distorts information on the 
actual distribution of a transdermally delivered drug within the 
tissue. Consequently, information about drug concentrations in the 
target tissue is only indirect, and artif.1cts may be pmduced. 
For more than a decade, nucrodialysis has been used as a method 
of continuous ;11 11;';0 sampling in neuropharmacology. The basic 
principle of microdialysis is to minuc the function of a capillary 
blood vessel by perfusion of a thin semipermeable dialysis tube 
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male volunteers receiVing nicotine by transdermal 
delivery, nicotine was detectable within 90-180 min, 
and peak levels of approximately 1000 ng/ml were 
detected within 240-360 min of patch application. 
Correlation analyses of the individual data from our 
subjects revealed that nicotine kinetics were inde-
pendent of skin barrier function, as assessed by trans-
epidermal water loss, but indicated that the detect-
able maximum nicotine levels may depend on the 
location of the probe. In summary, the present study 
demonstrates that micro dialysis may be a novel, pow-
erful tool to study cutaneous pharmacology ill vil'o. 
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implanted in the tissue. The dialysate is analyzed chenucally and, 
w ith regard to dialyzable molecules, mirrors the composition of the 
extracellular fluid (for review, see [2]). Recently, this technique has 
been adapted to determine drug concentrations in various periph-
eral organs, including adipose tissue [3] and muscle [4]. In human 
skin, the use of microdialysis has thus far been limited to deternu-
nations of endogenous molecules, such as glucose [5] and histantine 
[6,7], aJld has been used to measure skin barrier function [8]. 
Collectively, reports published thus far indicate that microdialysis 
might be a useful tool for studying the cutaneous pharmacology of 
epicutaJleously applied and traJlsdernlally delivered drugs. In the 
present study, we evaluated microdialysis as a novel ;/1. 1;;110 sampling 
teclm.ique for kinetic analyses of drug levels in human skin, using 
the transdermal application of nicotine as a model. 
MATEIUALS AND METHODS 
Microdialysis Tcchnique The microdialysis system (CMA / Microdialy-
sis AB, Stockh olm, Sweden) basicaJly consists ofa CMA/ 100 microinjection 
pump, which delivers stcrile Ringer's solution at low flow rates of 1-50 
ILl/min as perfusate to the probe, and a microfraction collector (CMA/140). 
The microdialysis probcs (CMA / 10; CMA/ Microdialysis AB) used in the 
prcsent study were custom made, with a shaft lengcll of 70 mm and a 
polycarbonate membrane of 10 mm in lcngcll. T hese probes, which are 
permeable to molccules of up to 20 kDa molecular weight, are identical to 
those described in detail in recent publications by Anderson et al [7,8]. 
All probes were stcrilized using ethylene Oldde before implantation. The 
sterilization procedure did not alter the physicochemical properties of the 
probes (data not shown). Before their use for ill "ilm and ;11 ";110 studies, cl,e 
probes were washed undcr sterile conditions, using Ringer's solution as 
both pcrfusatc (lOlLI/min) and dialysis medium, for a minimum of 60 min 
to remove residual ethylcne oxide. 
III Vitro Experiments The CMA/ IO probe was characterized ;11 vitro by 
performing microdialysis of ( - )lucotine (Sigma Chemical Co., St. Louis, 
MO) in Ringer's solu tion. In separatc experimcnts, the pcrfusion rate or the 
nicotine concentration was varied while leaving the other -Ilariable UJl-
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changed. For each condition tested, three samples of 300 ",I we re collected, 
and nicotine concentrations were determined . 
Subjects and Design of the Study Ten male vo lun teers aged 30 .0 ::':: 
2.0 years (mean ::':: SD; range 28-34 years) were recruited from the hospita l 
staff. All subjects were in good genera l health except for subject E, w ho 
suffered from atopic dermatitis, and subject 1-1, who had a seasonal atopic 
rhino-conjunctiviti s. Six subjects (A, fl, C, E, F, I) had no smoking histo ry, 
and three subjects (D, H ,J) smoked fewer than five cigarettes daily. Subject 
G was a smoker who has been consuming 20-30 ciga rettes per day since 
1988. All volunteers gave informed consent to parcicip<lte in the study , and 
the protocol was approved by the Ethics Committee of the University of 
Vienna (EK 122194). 
Volunteers were admitted to the Dermatopharmacology Unit, a stress-
free and air-conditioned (22°C) environment. Througho ut the study, the 
subjects remained in a supine position and were requested to refrain from 
smoking. AU experiments were performed at the sam e time of day. At 8:00 
AM, after subcutaneous local anesthesia with 2% lidocaine, the microdialysis 
probe was implanted according to a modified teclmique of Anderson e/ al 
[7,8). Briefly, a 20-gauge blood donor cannula was inserted strictly intra-
dennally, parallel to the surface of the skin into the right anteriorllateral 
thigh. The steel mandriJ1 was carefully removed and the probe was 
introduced into the cannula, ensuring that the fragile microdialysis m em-
brane at the tip of the probe rem ained inside the cannula. T he plastic 
caI1Jlula was tI,en retracted by 1.5 cm, which left the probe in a strictly 
intrademlal position para llel to the surface of the skin and exposed the 
dialysis membrane to the dennal microenvironment. Afte r introduction and 
positioning of the probe, the probe was connected to the microdialysis 
system and perfused with steril e Ringer's solution at a rate of l 0 ",l/min. For 
each subject, we obtained 16 samples of 300 ",I, corresponding to a 
coLlection time of 30 nun per sample. 
Witlun 45- 60 nUn of placement of the probe, tra nsepidemlal water loss 
as a measure of skin barrier function [9) was quantified in a skin area 5 cm 
proximal to ti,e test area using a Tewameter (Courage and Khazaka, 
Cologne, Germany). This instrument measures the water evaporation from 
a skin area of 0.79 c·m 2 in an open chamber (diameter 10 mm, height 20 
mm) . Depending o n the anatonuc site, values between 9.5 and 19.9 g/lun2 
are considered normal. * Afte r 60 min of baseline sampling, a medicated 
patch containing 35 mg S(-)Iucotine (Nicotinell TIS 20; C iba-Geigy 
Ges.m .b.I-I., Vienna, Austria) was administered, w ith the cen ter of the patch 
placed above the tip of the probe. Sampling was then continued for an other 
7 h . After the conclusion of sampling, the probe was disconnected from the 
system and the position of the probe was visualized using ul trasonography 
(for reviews, see [10,11)), using a Dennascan C equipped with a high-
frequency 20-MHz probe (Cortex Technology, Hadsund, Denmark). The 
depth of ti,e probe was detennined by measuring the distance between the 
inner aperture of the probe and the entry echo, based on a mean velocity of 
sound of 1580 m/second. Finally, the microdialysis probe and the plastic 
caI1J1 ula were removed, and the area of skin puncture was covered w ith a 
sterile dressing. 
Quantitative Assessment of Nico t ine T he concentration of luco tiJle 
in the dialysate was detemuned according to standard laboratory procedures 
using lugh performance liquid chromatography (1 2). In brief, nicotine was 
extracted at room temperature fro m the dialysate with an equal volume of 
organic chromatography eluent, consistiJlg of dichloromethane, dusopropyl 
etber, mcthanol, and 25% ammonia solution (62:30:7.9:0.1 by volume; 
E. Merck, Dan11Stadt, Gennany). High performance liquid chromatography 
was perfomled at a flow rate of 2.0 ml/ min using a Nucleosil 50-5 column 
(125 X 4 mm internal diameter; SRD F. Pannosch , Vienna, Austria). As 
detected by ultraviolet light (260 nm) absorbance, the lucotine peak elu ted 
at 2.7 min . Under these conditions, the detection limit for lucotine in tbe 
dialysate was 15 ng/ ml. The concentrations of nicotine in tbe samples were 
qU3Jltified by peak integration and by compari son of the respective peak 
arcas with those of standards containing known concentra tions of lucotinc. 
The relation betwecn the nicotine concentrations and tbc corresponding 
pcak arcas was linear up to a concentration of 0.1 mg/ml. Because tbc 
recovery after tbe extraction procedure was dependent on the concentration 
of nicotiJle in the sample (data not shown), aU standards were prepared in 
Ringer's solu tion and cxtracted in paraUel w ith the samplcs. 
Statistics Spearman correlation coefficients were calculated using com-
mercia l software (SAS Institute, Cary, NC). 
• Barel AO, C larys P: Study of the stratum corneum barrier r~lI1ction by 
transepidermal water loss measurements. Comparison between two com-
mercial instnlmcnts: Evaporimetcr® and Tewameter®. T be 9th Symposium 
on Bioengineering and the Skin, Sendai, Octobcr 19-20, 1992. 
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Figure 1. III vitro recovery o f nicotine depends on the perfusion rate 
but not on the nicotine concentration in the dialyzed medium. A, 
re lative recovery of lucotine at a concentration of 500 ng/ml in the m edium 
was dctermincd at different perfusion rates and was 12.7 ::t 0.79% at a rate 
of 10 ",l /min . B, increasing concentrations of nicotine werc tested at a 
perfusion rate of 10 ",lImin . 1" "i/,.o rccovery remained constant in the 
concentration range tested. All values presented arc m ean s ::t SD frOI11 six 
individual determinations. T be absence of error bars indicates that the SD 
was smaller than the symbol. 
RESULTS 
Characterization of the Microdialysis Probe In Vitro T h e 
rela tion b etween the concentrations of a substance in th e dia lysate 
and in the dialyzed tissue o r m e dium is termed "relative recovery" 
and is expressed as a p ercent value . T h e rela tive recovery is an 
importan t ch aracteristic of the microdia lysis pro b e and d e p e nds o n 
both th e substance investigated and the p erfu sion rate at which 
dialysis is performed. As d e termine d by microdialysis of an aq u eou s 
solu tion of nicotine in a known con ccntration (500 n g/ml) , th e 
relative recovery d ecreased with increasing perfu sion rates (Fig 
lA). At 10 ILl/min, th e rate u sed in a ll further experim e nts, r e lative 
rccovery was 12 .7 ::!:: 0.79% (mean ::!:: SD, n = 6; range 12.0-13.6 
ILl/min). 
T h e m icrodialysis probe was furth er ch aracterized b y performing 
dia lysis of Ringer's solu tion , containin g differen t con centrations of 
nicotine, at a perfusion rate of 10 ILl/min . As di splayed in Fig lB, 
th ere was a lin ear relation between the con centration s of nicotin e 
d etected in the dialysates and those in the dialyze d m e dia, thu s 
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Table I. Physical Parameters and Individual Kinetic Data of the Study Subjects· 
A 
B 
C 
o 
E 
F 
G 
H 
r 
J 
Subject 
Mean ± SO 
Age (years) 
28 
29 
28 
30 
34 
31 
31 
28 
29 
32 
30 ± 2.0 
Smoking 
History 
N 
N 
N 
S 
N 
N 
H 
S 
N 
S 
TEWL Probe Depth 
(g/ lll112) (111111) 
9.9 0.78 
11.3 0.61 
12.8 0.98 
10.9 1.22 
ND ND 
11.8 0.72 
13.6 0.57 
16.6 0.61 
10.4 0.84 
11.8 0.61 
12.1 ± 2.03 0.77 ± 0.215 
Onset emllx tUlax 
(Sample) (ng/ml) (sample) 
6 890 12 
5 760 14 
8 690 12 
5 500 12 
ND ND ND 
7 2140 13 
8 1510 14 
5 1430 11 
7 1930 11 
6 2100 13 
6.3 ± 1.23 1327.8 ± 639.18 12.4 ± 1.13 
" Ten healthy male subjects were studied: six non-smokers (N), three smokers (fewer than five cigarettes daily; S) and one heavy smoker (20 -30 cigarettes daily; H). Subject 
E developed a hematoma within the test area and was excluded from further evaluations. The physical paranlc ters, transcpidermal water loss (TEWL). and the depth of the 
mjcrodialysis pro be were documented and correlated with the nicotine kine tics of the same individual. The onset of the nicotine peak and the peak nicotine concentration (cm ax) 
and time (tnmx) arc presented . ND, not done. 
demonstrating that the relative recovery remained constant in the 
concentration range tested (0-50 J.Lg/ml). 
Clinical Observations and Physical Measurements The 
study procedures, particularly insertion of the micro dialysis probe 
under local anesthesia, did not cause any noteworthy discomfort to 
the volunteers. During the study period, no systemic or local 
adverse reactions were noted except in subject E, who developed a 
hematoma within the test area and was therefore excluded from 
further evaluations. 
Within 45-60 min after placement of the probe, we quantified 
transepidermal water loss using a Tewameter. The measurements 
did not indicate alterations of skin barder function in any of the 
study subjects (Table I) , displaying a value of 12.1 ± 2.03 g/hm2 
(n = 9; range 9.9-16.6 g/lun2). In all subjects, the location of the 
probe was determined using ultrasonography after completion of ill 
vivo sampling and removal of the nicotine patch . Representative 
pictures , taken from ultrasonography of subject H, are shown in 
Fig 2 . The depth of the probe, i.e ., the distance between the inner 
aperture of the probe and the entry echo, was 0.77 ± 0.215 mm 
(n = 9) with a range of 0.57-1.22 mm, thus indicating that the 
probe was located within the dermis. 
Kinetic Analysis of Nicotine Levels in Human Dermis The 
time course of nicotine levels in the dialysate of human dermis for 
all volunteers is depicted in Fig 3. The first two samples were 
collected before administration of the medicated patch and thus 
represent nicotine concentrations at baseline. In all subjects inves-
tigated, regardless of their smoking habits, nicotine levels at 
baseline were below the detection limit of 15 ng/ml (data not 
shown). After administration of the patch, nicotine concentrations 
in the dialysate increased gradually, peaked within 330-360 min at 
a level of 1113 .6 ± 622.3 ng/ ml, and remained at approximately 
1000 ng/ml throughout the subsequent sampling period, thus 
indicating steady-state conditions (Fig 3). Evaluation of the indi-
vidual kinetic data (Table I) revealed an onset of the nicotine peak 
at sample 6.3 ± 1.23, i.e. , be tween 120 and 150 min after patch 
administration, and a maximum nicotine concentration in the 
dialysate of 1327.8 ± 639.18 ng/ml. 
Correlation of Kinetic Data with Physical Characteristics 
Because the onset of the nicotine peak and the ma.umum nicotine 
levels in the dialysate showed rather large inter-individual differ-
ences, we attempted to correlate the individual kinetic data from 
our subjects with their physical characteristics (Table I) . All 
subjects were of similar age, with a range of 28-32 years. There-
fore , it seemed unlikely that age-related alterations of drug metab-
olism or skin structure would influence the kinetics. The subjects 
were heterogeneous with respect to smoking history, but no direct 
correlation was apparent between smoking habits and the kinetics 
of nicotine (data not shown). To test a possible influence of skin 
barrier function or probe depth on the kinetic data, we calculated 
Spearman correlation coefficients. As listed in Table II, no corre-
lations could be established for the kinetic data verslIs transepider-
mal water loss and the onset of the nicotine peak verslIs the probe 
depth. However, the statistical analysis indicated that the latter 
parameter might influence the detectable maximum nicotine level 
and the time of its occurrence, but the respective correlation 
coefficients did not reach significance at a level of p < 0.05. 
DISCUSSION 
Microdialysis is a well- established method of continuous ill vivo 
sampling in n europharmacology (for review, see [13]) . Originally 
designed for the determination of neurotransmitters and other 
endogenous substances in different brain areas of the laboratory rat, 
the applications of microdialysis have recently been extended with 
respect to both the substances and the tissues investigated. Studies 
using microdialysis for detection of systemically administered drugs 
in human peripheral tissue [3], together with reports concerning the 
use of microdialysis to analyze endogenous substances in human 
skin [5-7], prompted us to evaluate this technique for kinetic 
analyses of cutaneous drug levels in man. Nicotine, incorporated in 
a transdermal delivery system (Nicotinell ITS 20), was chosen as a 
model because its pharmacodynamic and pharmacokinetic proper-
ties have been documented thoroughly [14,15]. 
Before performing microdialysis in a clinical setting, it is essential 
to investigate the properties of the probe ill vitro (for review, see 
[2]). U sing a CMA/l0 probe witll a membrane length of10 mm at 
a perfusion rate of 10 J.Ll/min, we obtained a relative recovery of 
nicotine of approximately 13%. Lower flow rates yielded higher 
recovery but required sampling for longer than 30 min to reach a 
volume sufficient for quantitative drug analysis, which would have 
been a disadvantage in the present study. Nicotine levels in the 
dialysate strictly correlated witll nicotine concentrations in the 
dialyzed medium, as the relative recovery remained constant over 
the entire range of relevant concentrations. 
Using a modification of the technique of Anderson et aT [7,8], we 
were able to place the microdialysis probe into the human dennis 
parallel to tile surface of the skin. This was verified by means of 
ultrasonography, which revealed a mean probe depth of 0.77 mm. 
Introduction of the probe into the dennis, as opposed to the 
subcutis, made local anesthesia absolutely necessary to avoid the 
considerable pain associated with placement of the cannula. How-
ever, even in anestlletized skin, probe introduction has been 
associated with patl1Ophysiologic changes in the skin, such as an 
increase in blood flow for up to 60 min after probe insertion [16] . 
Therefore, tile nicotine patch was administered 60 min after probe 
insertion. This period also allowed probe equilibration i.n the dermis 
and collection of baseline samples. 
None of the subjects demonstrated detectable nicotine levels 
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Figure 2. Representative 20-MHz ultrasonography from subject H. The microdialysis probes were localized within the dermis (A) and were parallel 
to the surface of the skiJl (B) (longitudinal B-scan). 
before application of the medicated patch. However, our method of 
drug analysis bad a detection limit of15 ng/ml , and our ill vitro data 
indicate that the nicotine concentrations in the dialyzed ti ssue or 
m edium may be about 10-fold higher than those detected in the 
dialysate . T herefore, on the basis of our data, we cannot exclude 
that nicotine levels in the low nanomolar range might have been 
present in some individuals. Nicotine levels were first detected 
.dmlnl.tr.Uon of nicotine patch 
umple 10 11 12 13 14 15 18 
.tudy time (min) 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 
Figure 3. Pharmaeokinetic data may be obtained from human skin 
using micro dialysis. The time course of nico tine levels in the dia lysate of 
human dem1is (n = 9) is shown. For each 30-min sample, the individual 
data points and the corresponding means 1: SD (bars) are depicted . As a 
representative kinetic, data points of subject A are displayed on a curve. 
between 60 and 180 min after patch application. The onset of the 
nicotine peak correlated with neither the depth of the probe nor 
transepidermal water loss and might thus depend on variables that 
were not assessed in the present study, such as the individual lipid 
composition of the skin [17] . Dermal concentrations of nicotine 
were found to reach a plateau 240-360 min after patch application, 
which correlates with nicotine blood levels reportedly reaching a 
maximum after 7-9 of patch application [14] . T he maximum levels 
of nicotine in the samples showed large inter-individual differences, 
ranging from 500 to 2140 ng/ml. There was some evidence that the 
maximum drug level and the time of its occurrence might be 
influenced by the exact position of the probe. Although the probe 
was localized within the dermis and the test site was identical in all 
volunteers studied, differences in the dermalmicrocompartments to 
Table II. Correlation Analysis Between Nicotine 
Kinetics and Physical Parameters" 
Nicotine Peak 
Onset CIIH1X till" ,," 
TEWL 0.216 0.1 42 0.155 
Probe depth 0.000 - 0.475 - 0.559 
/ 1 Spcamlan correlation coefficients were calculated from the individua l volunteer 
data to tcst " possible influence of transepidcrmal water loss (TEWL) or probe depth 
on the kinetics of nicotine. T he onset of the nicotine peak :md the peak concentration 
(emil )!:) and time (tlll:uJ were cvahmtcd. Correlation coefficients did not reach signifi-
cance at a level of p < 0.05. 
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which the microdialysis membrane was exposed, such as the lower 
papillary body or superficial reticular dermis, may account for the 
differences seen in the individual maximum nicotine levels. T lus 
rather prelintinary observation may stimulate further investigations 
in a larger number of volunteers. 
The present study was designed to monitor the time course of 
nicotine concentrations in human skin rather than to determine 
absolute drug levels . Indeed, the changes in nicotine levels in the 
samples truly reflected those in the dialyzed medium, as attested by 
the constant relative recovery in our in. Jlitro experiments . Never-
theless, it is tempting to speculate about the absolute nicotine 
concentrations in human skin during administration of the patch . 
Assuming that the relative recovery of nicotine in human skin is 
similar to that determined ill rJitro, dermal nicotine concentrations 
would be at a level of about 4- 18 fLg!ml, i.e., SOD-fold higher than 
the corresponding plasma concentration [14]. Although the exact 
absolute tissue concentrations must be determined in separate 
investigations, the great difference between dermal nicotine levels 
and the corresponding plasma concentrations may reflect local 
vasoconstriction induced by lucotine (for review, see [18]). 
In summary, the present study demonstrates that relevant phar-
macokinetic data may be obtained in the skin using microdialysis. 
Tlus opens a new field for studies on the dermal pharmacokinetics 
of topically applied drugs and! or their metabolites, provided they 
are dialyzable and are present witl1i.n the tissue and dialysate at a 
level above the detection threshold . Within the general linuts of 
the tecluuque [2,19] , micro dialysis may thus be considered a 
powerful tool to study cutaneous pharmacology. 
Hi e are illliebled 10 Peler DOllall" MD, for /Jeljorlllillg Ihe slatisliCtlI allalyses. 
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